Jun 08, 2022
|
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
|
|
Jun 06, 2022
|
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
|
|
Jun 02, 2022
|
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
|
|
May 31, 2022
|
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
|
|
May 18, 2022
|
Suketu Upadhyay Elected to Vertex Board of Directors
|
|
May 17, 2022
|
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
|
|
May 17, 2022
|
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
|
|
May 05, 2022
|
Vertex Reports First Quarter 2022 Financial Results
|
|
May 02, 2022
|
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
|
|
Apr 21, 2022
|
Vertex to Announce First Quarter 2022 Financial Results on May 5
|
|
Apr 20, 2022
|
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
|
|
Mar 31, 2022
|
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
|
|
Mar 26, 2022
|
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
|
|
Mar 22, 2022
|
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
|
|
Mar 01, 2022
|
Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8
|
|
Jan 26, 2022
|
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
|
|
Jan 18, 2022
|
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
|
|
Jan 11, 2022
|
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
|
|
Jan 04, 2022
|
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
|
|
Dec 01, 2021
|
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
|
|